Jardiance vs Tresiba: What to Do When One Fails

How Each Drug Actually Works

Jardiance and Tresiba do not compete in any meaningful pharmacological sense. They address different aspects of glucose dysregulation, and understanding that distinction is the first step toward knowing what to do when either one stops delivering results.

Empagliflozin: Blocking Glucose Reabsorption

Empagliflozin inhibits sodium-glucose cotransporter-2 (SGLT2) in the proximal renal tubule, forcing the kidney to excrete roughly 70-90 grams of glucose per day in urine. [1] The mechanism is insulin-independent, which means it works even when beta-cell function is severely diminished, though its glycemic effect shrinks proportionally as eGFR falls. Below an eGFR of 45 mL/min/1.73 m², the FDA label for Jardiance now restricts use to its cardiorenal indications rather than glucose lowering. [2]

Insulin Degludec: Replacing What the Pancreas No Longer Secretes

Insulin degludec forms soluble multi-hexamer chains at the injection site, releasing monomers slowly over a half-life of roughly 25 hours. This produces a flat, peakless plasma-insulin profile that lasts beyond 42 hours in most patients. [3] Unlike empagliflozin, degludec does not depend on kidney function to lower glucose. It works as long as tissue insulin sensitivity remains sufficient and the dose is calibrated correctly.

EMPA-REG OUTCOME and DEVOTE: What the Trials Actually Measured

Neither trial was designed as a head-to-head comparison between these two drugs. Reading them together, though, reveals the different patient populations each agent was built for.

EMPA-REG OUTCOME (2015)

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% relative to placebo (hazard ratio 0.86, 95% CI 0.74-0.99, P<0.001 for non-inferiority and P=0.04 for superiority). [1] Cardiovascular death alone fell by 38%. The mean HbA1c difference versus placebo was only 0.4-0.5 percentage points, suggesting the cardiovascular benefit outran what glycemic control alone could explain.

DEVOTE (2017)

DEVOTE compared insulin degludec with insulin glargine U-100 across 7,637 patients with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior to glargine on MACE (hazard ratio 0.91, 95% CI 0.78-1.06). [4] The more clinically important finding: degludec produced 40% fewer severe hypoglycemic episodes than glargine (rate ratio 0.60, 95% CI 0.48-0.76, P<0.001). HbA1c reductions were similar between arms, confirming the trial differentiated on safety rather than efficacy.

What These Trials Do Not Tell You

Neither EMPA-REG OUTCOME nor DEVOTE enrolled patients who had already failed the comparison drug. They were not switch trials. Extrapolating "Jardiance failed, so Tresiba is next" from these datasets is not supported by the data.

When Jardiance Fails: Recognizing the Pattern

"Failure" with Jardiance almost always falls into one of three categories: insufficient glycemic effect from the start, loss of effect over time as eGFR declines, or a safety-driven discontinuation. Identifying which category applies determines whether insulin is actually the logical next step.

Inadequate Initial Response

Patients with a baseline HbA1c above 9% are unlikely to reach target on empagliflozin alone or empagliflozin added to metformin. The drug's ceiling effect means it reduces HbA1c by roughly 0.5-0.8 percentage points from baseline in most add-on trials, [5] which is insufficient to normalize glucose when the patient starts far above goal. That is not failure. It is a dosing-ceiling issue, and the correct response is adding a second agent with complementary efficacy, not necessarily removing empagliflozin.

Declining Kidney Function

As renal glucose excretion capacity shrinks with falling eGFR, Jardiance's glycemic contribution diminishes. Once eGFR drops below 45 mL/min/1.73 m², the drug can no longer be used for glucose control. [2] Patients in this position are also at higher cardiovascular and kidney risk, which argues for careful selection of the next agent. Basal insulin (including degludec) is renally safe; dose adjustments may still be needed due to altered insulin clearance at low eGFR.

Safety-Driven Discontinuation

Recurrent genital mycotic infections, urinary tract infections, or a history of diabetic ketoacidosis (particularly in patients misclassified as type 2 who are actually type 1 or LADA) are legitimate reasons to stop empagliflozin. These patients often need insulin as replacement, not just supplementation. Insulin degludec becomes a reasonable basal-insulin foundation in that scenario.

When Tresiba Fails: Recognizing the Pattern

Insulin degludec "failure" is more often a dosing or regimen problem than a true pharmacological ceiling. Still, certain patterns signal that degludec alone is no longer sufficient.

Basal Dose Creep Without Prandial Coverage

The most common failure mode is progressive basal dose escalation without addressing postprandial excursions. If a patient's Tresiba dose exceeds 0.5 units/kg/day and fasting glucose is controlled but HbA1c remains above 8%, the problem is almost certainly postprandial glucose, which no basal insulin, including degludec, is designed to manage. The solution is a prandial agent, a GLP-1 receptor agonist, or an SGLT2 inhibitor such as empagliflozin, not a switch away from Tresiba. [6]

Dawn Phenomenon Uncontrolled by Single Daily Dosing

Some patients experience a significant rise in early-morning glucose driven by cortisol and growth-hormone peaks. Degludec's ultra-flat profile generally handles this better than glargine, but extreme dawn-phenomenon responders may still see fasting glucose above target. Repositioning the injection time or adding a small dose of a morning SGLT2 inhibitor can stabilize this without abandoning basal insulin.

True Insulin Resistance

Patients with severe obesity and insulin resistance (total daily doses above 1.5-2 units/kg) may see diminishing returns from degludec. Empagliflozin added to a high-dose basal regimen can reduce total daily insulin requirements by 10-20% in some patients [7] while providing the cardiovascular benefit documented in EMPA-REG OUTCOME. [1] In this scenario, the two drugs work together rather than one replacing the other.

Can You Combine Jardiance and Tresiba?

Yes, and this combination is well-studied. Adding empagliflozin to basal-insulin regimens has been evaluated in multiple trials, consistently showing HbA1c reductions of 0.5-0.9 percentage points beyond insulin alone, with body-weight reductions of 1-3 kg and modest blood-pressure benefits. [7] The main safety consideration is euglycemic DKA, a rare but serious complication in which acidosis occurs despite near-normal glucose. Risk is highest during illness, prolonged fasting, alcohol use, or excessive insulin dose reduction after starting an SGLT2 inhibitor.

The 2024 American Diabetes Association Standards of Care state that in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, SGLT2 inhibitors should be considered independently of HbA1c or existing glucose-lowering therapy. [6] That means empagliflozin's cardiovascular indication persists even when insulin degludec is already prescribed.

A Practical Decision Framework for Combination Therapy

1. Start empagliflozin at 10 mg once daily and monitor for volume depletion over the first 2-4 weeks, especially in patients on diuretics.
2. Do not reduce Tresiba proactively when starting empagliflozin. Instead, establish a hypoglycemia protocol with the patient and reduce the basal dose only if confirmed low blood glucose occurs.
3. Recheck HbA1c and fasting glucose at 12 weeks. If fasting is now controlled but HbA1c remains above target, evaluate postprandial excursions before adjusting either drug.
4. Hold empagliflozin at least 3 days before any planned surgery or prolonged fasting of more than 12 hours to reduce euglycemic DKA risk.

Switching: When a Direct Swap Is Actually Appropriate

A true switch from Jardiance to Tresiba, or from Tresiba to Jardiance, is less common than adding the second agent. The scenarios where a direct switch makes sense are narrower than most patients expect.

Appropriate Switch from Jardiance to Tresiba

• Beta-cell function is severely depleted (C-peptide below 0.6 ng/mL) and insulin is medically necessary. [8]
• Patient has recurrent SGLT2-related DKA or cannot tolerate genital infections despite hygiene counseling.
• eGFR has fallen below 45 mL/min/1.73 m² and glycemic control is the primary indication for Jardiance.

In these situations, starting Tresiba at 10 units once daily (or 0.1-0.2 units/kg) with weekly titration by 2 units until fasting glucose reaches 80-130 mg/dL is a standard initiation approach aligned with ADA guidance. [6]

Appropriate Switch from Tresiba to Jardiance

This switch is appropriate when a patient has been using low-dose basal insulin primarily as a compensatory measure for lifestyle-related hyperglycemia, retains meaningful C-peptide secretion, has established cardiovascular disease or heart failure, and is willing to trial SGLT2-based management alongside lifestyle changes.

The 2023 ESC guidelines on diabetes and cardiovascular disease assign empagliflozin a Class I, Level A recommendation for patients with type 2 diabetes and heart failure with reduced or preserved ejection fraction, independent of HbA1c. [9] If cardiovascular risk is driving the treatment choice, the switch to empagliflozin is not merely permissible, it is guideline-supported.

Safety Profiles Side by Side

Understanding the safety differences helps clinicians and patients weigh the risk-benefit ratio at each decision point.

Hypoglycemia

Empagliflozin alone does not cause hypoglycemia because its mechanism is insulin-independent. Tresiba carries a meaningful hypoglycemia risk, but DEVOTE showed it is significantly lower than insulin glargine U-100: 40% fewer severe episodes over a median 2-year follow-up. [4] When combined, the SGLT2 inhibitor does not add hypoglycemia risk, but over-reduction of the Tresiba dose when starting empagliflozin can destabilize glycemic control in the other direction.

Cardiovascular Events

Empagliflozin's 38% reduction in cardiovascular death in EMPA-REG OUTCOME [1] is one of the most pronounced cardiovascular benefits ever documented for a glucose-lowering agent. Insulin degludec in DEVOTE was cardiovascularly safe but did not demonstrate superiority over glargine on hard cardiovascular endpoints. [4] For a patient with established atherosclerosis or heart failure, this difference in the evidence base matters when choosing primary therapy.

Body Weight

Empagliflozin produces modest weight loss (1-3 kg in most trials) through glycosuria. Tresiba is weight-neutral to mildly weight-gaining. Patients who are obese and insulin-resistant may find the empagliflozin weight effect clinically useful alongside basal insulin.

Kidney Function

Empagliflozin slows eGFR decline and reduces progression to end-stage kidney disease, as confirmed in the EMPA-KIDNEY trial (N=6,609), where empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% relative to placebo (hazard ratio 0.72, 95% CI 0.64-0.82, P<0.001). [10] Insulin degludec does not confer independent nephroprotection, though it is safe to use across a wide range of eGFR values.

Dosing Reference

Empagliflozin (Jardiance) Dosing

• Starting dose: 10 mg orally once daily, morning preferred.
• Escalation: May increase to 25 mg once daily if additional glycemic control is needed and eGFR is above 45 mL/min/1.73 m².
• Heart failure indication: 10 mg once daily regardless of diabetes status.
• CKD indication: 10 mg once daily when eGFR is 20 mL/min/1.73 m² or above.

Insulin Degludec (Tresiba) Dosing

• Insulin-naive type 2 diabetes: 10 units subcutaneously once daily at any time, same time each day.
• Titration: Increase by 2 units every 3 days until fasting plasma glucose is 80-130 mg/dL.
• Flexible dosing: Degludec's long half-life allows dose-timing flexibility of up to 8-9 hours between injections without loss of glycemic control, a feature not available with glargine or detemir. [3]
• Conversion from other basal insulins: Switch unit-for-unit from glargine U-100 or NPH, then titrate as needed.

What the HealthRX Medical Team Sees Clinically

In the HealthRX telehealth patient cohort, the most common reason patients are incorrectly switched from Jardiance to Tresiba (rather than having Tresiba added) is a provider who interprets an HbA1c above 8% as proof that empagliflozin "failed," without recognizing that the baseline HbA1c was 9.5% and the patient has documented heart failure with reduced ejection fraction. Removing empagliflozin in that patient strips away a guideline-supported cardiovascular protective agent on the basis of a glycemic metric it was never powerful enough to achieve alone. The right response is keeping empagliflozin, adding Tresiba, and adjusting insulin to fasting targets.

Drug Interactions and Practical Cautions

Empagliflozin has minimal cytochrome P450 interactions. It is excreted primarily via glucuronidation (UGT2B7 and UGT1A3), so it rarely affects or is affected by other common diabetes medications. Tresiba interacts indirectly with any drug that alters insulin sensitivity, including corticosteroids (which raise requirements), fluoroquinolones (which can cause unpredictable glucose swings), and beta-blockers (which blunt hypoglycemia symptoms). Patients on both agents must receive written sick-day rules covering when to hold empagliflozin and when to contact their provider about Tresiba dosing during illness.

Practical Takeaways for Patients

• Jardiance controls blood sugar through the kidneys. Tresiba replaces the insulin your pancreas is no longer making in sufficient amounts. They do different jobs.
• If Jardiance is not lowering your HbA1c enough, the answer might be adding Tresiba, not dropping Jardiance.
• If Tresiba alone is not controlling your HbA1c despite a controlled fasting glucose, your postprandial spikes are the problem, and an SGLT2 inhibitor like Jardiance may help fill that gap.
• Always ask your provider whether your kidneys are healthy enough for Jardiance before starting or continuing it. An eGFR test answers that question in minutes.